YOLFTbeta
GenoFocus Inc

GenoFocus Inc

187420 · KQ · Basic Materials / Specialty Chemicals

1,825.00KRW-93.00 (-4.85%)

Price History

Full chart

Market Stats

Previous Close1,918.00
Open1,945.00
Day Range1,821.00 – 1,946.00
52-Week Range1,323.00 – 3,680.00
Volume129.15K
Market Cap62.19B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.08
50-Day Avg1,811.82
200-Day Avg2,354.93

About

HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phytosphingosine and vitamin K2. The company also develops drug candidates for wet and dry macular degeneration, inflammatory bowel disease, anticancer, oral mucositis, nonalcoholic steatohepatitis, diabetic macular edema, and dry eye indications. The company was formerly known as GenoFocus, Inc. HLB Genex, Inc. was founded in 2000 and is based in Daejeon, South Korea.

Company Details

  • SectorBasic Materials
  • IndustrySpecialty Chemicals
  • CEOMr. Eui-Joong Kim
  • Employees74
  • Headquarters65 Techno 1-ro, Daejeon, South Korea, 34014, Korea
  • Websitehttps://hlbgenex.com

Leadership

  • Mr. Eui-Joong KimChief Executive Officer
  • Jae-Gu PanFounder & CTO

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue6.15B6.64B7.03B11.51B11.52B14.94B18.77B25.87B27.80B27.01B35.43B43.37B
Growth (%)-+8.00%+5.85%+63.70%+0.10%+29.72%+25.62%+37.85%+7.45%-2.85%+31.18%+22.41%
Cost of Revenue3.63B4.29B4.03B8.11B9.93B11.25B12.71B16.04B17.59B19.68B21.13B28.18B
Gross Profit2.52B2.35B3.00B3.39B1.59B3.70B6.06B9.83B10.22B7.33B14.30B15.19B
Gross Margin40.98%35.39%42.70%29.48%13.77%24.73%32.28%38.00%36.74%27.14%40.36%35.03%
Operating Expense1.13B1.25B1.68B3.03B4.70B8.58B14.41B13.67B17.41B6.83B14.92B13.92B
Operating Income1.39B1.10B1.33B359.95M-3.11B-4.89B-8.35B-3.83B-7.20B498.20M-621.25M1.28B
Operating Margin22.63%16.54%18.87%3.13%-27.04%-32.70%-44.50%-14.82%-25.88%1.84%-1.75%2.94%
EBITDA---------565.90M9.36B-8.15B39.37B
EBITDA Margin---------2.04%34.65%-23.02%90.78%
Net Income2.18B1.21B1.61B1.41B-2.32B-5.76B-12.22B-6.82B-12.97B-2.95B-18.83B22.59B
Net Income Margin35.48%18.24%22.97%12.26%-20.11%-38.53%-65.09%-26.35%-46.64%-10.92%-53.14%52.09%
R&D243.97M136.05M265.17M352.42M899.04M4.26B8.03B10.41B11.68B11.61B10.27B5.90B
R&D as % of Total Revenue3.97%2.05%3.77%3.06%7.81%28.51%42.76%40.25%42.02%42.98%28.99%13.61%
Interest Expense0000002.09B3.96B6.33B5.51B4.26B11.00B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%11.14%15.32%22.76%20.39%12.02%25.35%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets16.94B30.52B63.23B70.15B70.33B90.20B113.23B118.52B133.91B97.86B146.26B135.83B
Total Liabilities7.28B736.18M709.87M5.93B10.12B38.08B73.46B83.24B110.02B71.50B122.49B81.08B
Total Equity9.66B29.79B62.52B64.22B60.21B52.12B39.77B35.28B23.89B22.04B23.77B40.92B
Cash5.29B9.30B21.28B3.16B2.78B13.06B22.03B25.11B11.01B22.89B83.81B33.48B
Total Debt---2.60B5.63B28.08B33.35B-----
Net Debt------39.32B52.37B67.32B39.04B-9.36B

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-286.45M2.85B516.09M1.36B1.56B-167.50M-2.45B-2.39B-4.71B-4.82B2.87B3.50B
Investing Cash Flow-5.62B-10.75B-38.31B1.20B-2.58B-14.01B-25.39B-6.93B-13.11B38.01B6.45B-
Financing Cash Flow4.86B11.96B30.98B-1.87B642.43M24.50B30.13B-35.73M22.91B-21.30B51.36B-
Capital Expenditure4.68B8.14B5.46B2.06B7.42B8.43B14.33B9.35B4.32B1.33B699.16M1.08B
Free Cash Flow-------18.06B-11.74B-9.03B-6.15B2.17B2.43B
FCF to OCF------736.58%491.24%191.69%127.68%75.64%69.27%

Earnings

Report DateAug 31, 2015Nov 26, 2015Mar 2, 2016May 27, 2016Aug 25, 2016May 15, 2017Aug 14, 2017Nov 14, 2017Feb 14, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Feb 22, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Feb 17, 2020Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------------------------------------
EPS Actual19.4445.15-9.4811.1920.9327.0521.7113.08-2.8238.72-25.85-18.84-98.964.05-43.98-125.83-99.730.06-35.23-91.98-416.71-41.1087.30-95.08-254.58-103.3768.80-103.63-437.68-136.1870.54-201.95134.90-68.447.69-27.41-712.05-44.50427.74-131.20214.86-84.62203.52
Surprise-------------------------------------------
TimingPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market--------------------------

Key Statistics & Ratios

Market Cap62.19B
Enterprise Value64.35B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.36
Price / Book1.08
Revenue (TTM)45.67B
Gross Profit (TTM)16.33B
EBITDA5.39B
Profit Margin20.28%
Operating Margin8.73%
Return on Equity16.75%
Return on Assets0.48%
Shares Outstanding32.64M
Shares Float21.63M
Beta0.08
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Mar 19, 20182:1